Vaxcyte, Inc. (PCVX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$61.16-0.02%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PCVX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PCVX — General Counsel transition
Dated 2026-09-03
Chief Legal Officer — David McAvoy: The filing discloses the appointment of a new Chief Legal Officer and Corporate Secretary, with the previous General Counsel retaining a senior role, indicating an internal succession or role expansion rather than a departure.
Why it matters: This report will show if Vaxcyte can improve its financial situation. Investors will look for signs of recovery.
Watch forEarnings report shows revenue growth turning positive year over year.
Also watch forEarnings report shows continued revenue decline or losses.
Why it matters: If health care sector growth speeds up, it could help Vaxcyte's performance. This would signal a better environment.
Supportive ifSector revenue growth exceeds 10% year over year.
Worry ifSector revenue growth remains below 10% year over year.
Why it matters: Starting this study is crucial for VAX-A1's development. It could lead to a new vaccine.
Supportive ifThe Phase 1 study for VAX-A1 is initiated as planned in mid-2026.
Worry ifThe initiation of the VAX-A1 Phase 1 study is delayed or canceled.
Why it matters: Starting this study is key for Vaxcyte's growth plans. It shows progress in their pipeline.
Supportive ifA press release confirming the start of the VAX-31 Adult Pivotal Study.
Worry ifNo news about starting the VAX-31 Adult Pivotal Study.
Why it matters: These results give more data on how well VAX-31 works. They help VAX-31 enter the market.
Supportive ifResults from OPUS-2 and OPUS-3 trials show VAX-31 is safe and has good immunogenicity.
Worry ifResults from OPUS-2 and OPUS-3 trials create doubts about VAX-31's ability to succeed in the market.
Why it matters: The OPUS-1 trial data will show if VAX-31 is effective against pneumonia. This could support a future vaccine launch.
Supportive ifThe OPUS-1 trial shows it is safe and tolerable. It also has good immune response data.
Worry ifVAX-31 does not meet the noninferiority criteria for PCV20 and PCV21.
Why it matters: This study's progress is crucial for Vaxcyte's product pipeline. Delays could hurt investor confidence.
Supportive ifAn announcement confirming the Modified Study is on track for Q3 2025.
Worry ifThere is a delay or cancellation of the Modified Study set for Q3 2025.
Why it matters: Cash levels impact Vaxcyte's ability to fund trials and operations. A drop could raise concerns.
Worry ifCash, cash equivalents, and investments remain above $2.5 billion as of Q3 2026.
Less concerning ifCash drops below $2.5 billion. This may mean funding problems.
Why it matters: These results will show how well VAX-31 works compared to current vaccines. Good results could help it enter the market.
Supportive ifResults from OPUS-2 and OPUS-3 trials expected in the first half of 2027.
Worry ifResults from OPUS-2 and OPUS-3 trials show VAX-31 is less effective than expected.
Why it matters: Updates on cash reserves will show if Vaxcyte can fund its clinical trials and growth plans.
Watch forCash position is stable or increasing. This shows strong financial health.
Also watch forCash position drops a lot, raising worries about funding for trials.
Why it matters: Data from VAX-A1 will show progress in making a vaccine for Group A Strep. This is an important health issue.
Supportive ifThe VAX-A1 Phase 1 study shows it is safe. It also has good immune response results.
Worry ifThe VAX-A1 Phase 1 study shows safety problems. It also shows low immune response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$178 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $353 loss on $10,000 · 3.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,795 loss on $10,000 · 28.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.